Approval · Notice of Compliance 7746 · 2006
AMERGE: Notice of Compliance 7746
Issued February 13, 2006
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 7746
- Date
- February 13, 2006
- Company
- Glaxosmithkline IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Inclusion of statement <not intended for the prophylactic therapy of migraine> in the product monograph
- Therapeutic class
- 5-ht1 receptor agonist, migraine therapy
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| AMERGE | Not yet assigned | — |
Medicinal ingredients
- NARATRIPTAN HCL 1 MG per TAB
- NARATRIPTAN HCL 2.5 MG per TAB